ArticleAlzheimer's & dementia (Amsterdam, Netherlands)2021
Comparing CSF amyloid-beta biomarker ratios for two automated immunoassays, Elecsys and Lumipulse, with amyloid PET status.
Article in Alzheimer's & dementia (Amsterdam, Netherlands), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 47 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
47 citing papers in PubMed.
- Inflammatory plasma biomarkers in subjects with preclinical Alzheimer's disease.Alzheimer's research & therapy · 2022Trial
- Cerebrospinal Fluid Biomarker Ratio Concordance with Amyloid Positron-Emission Tomography: A Diagnostic Test Accuracy Meta-analysis.Neurology and therapy · 2026Article
- Plasma Alzheimer Biomarkers and Diagnostic Decision-Making in Memory Clinics.JAMA network open · 2026Article
- The potential of key Alzheimer's plasma biomarkers to mimic tau PET MUBADA-based disease staging.Alzheimer's research & therapy · 2026Article
- Longitudinal Change in Blood-Based Biomarkers and the Association With MRI-Measured Neurodegeneration in Cognitively Unimpaired Individuals.Neurology · 2026Observational
- Real-world diagnostic performance of blood-based biomarkers for Alzheimer's disease: robust performance except after stroke and high charlson comorbidity index.Alzheimer's research & therapy · 2026Article
- Real world clinical practice of lecanemab at PUMCH dementia cohort: focus on dynamic imaging and biomarker evolution.Alzheimer's research & therapy · 2026Article
- Mild behavioural impairment-apathy and core Alzheimer's disease cerebrospinal fluid biomarkers.Brain : a journal of neurology · 2025Article
- Association of blood-based neurodegenerative biomarkers with cognitive functioning and dementia in India (LASI-DAD) and the United States (HRS).American journal of epidemiology · 2025Article
- Evaluation of preanalytical factors on quantification of amyloid-β (1-42), phosphorylated tau 181, and total tau in cerebrospinal fluid.Laboratory medicine · 2025Article
- Concordance between amyloid PET and CSF biomarkers in clinical setting: a cross-platform comparison and in-depth analysis of discordant cases.Scientific reports · 2025Article
- Impact of preanalytical delay on the performance of plasma Aβ42, Aβ42/40, p-tau217, and p-tau217/Aβ42 in detecting brain amyloidosis in the ALZAN cohort.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025Article
- Cerebrospinal Fluid Amyloid and Tau Biomarker Changes Across the Alzheimer Disease Clinical Spectrum.JAMA network open · 2025Article
- Novel CSF β-synuclein-specific assays signal early synaptic degeneration in Alzheimer's disease.Alzheimer's research & therapy · 2025Article
- Comparison of ERlangen Score with pTau/Aβ1-42 Ratio for Predicting Cognitive Decline and Conversion to Alzheimer's Disease.Brain sciences · 2025Article
- Considerations in the clinical use of amyloid PET and CSF biomarkers for Alzheimer's disease.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025Review
- Sink-index: a network-based EEG marker for frontotemporal dementia and Alzheimer's disease.Brain communications · 2025Article
- Longitudinal associations between amyloid and symptoms of depression and anxiety in subjective cognitive decline: the impact of personality characteristics.Frontiers in psychiatry · 2025Article
- Analytical and clinical validation of a high accuracy fully automated digital immunoassay for plasma phospho-Tau 217 for clinical use in detecting amyloid pathology.Frontiers in neurology · 2025Article
- Plasma p-tau immunoassays in clinical research for Alzheimer's disease.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionWe evaluated for two novel automated biomarker assays how cerebrospinal fluid (CSF) amyloid beta (Aβ)
methodsWe selected 288 individuals from the Amsterdam Dementia Cohort across the Alzheimer's disease clinical spectrum when they had both CSF and amyloid PET visual read available, regardless of diagnosis. CSF Aβ
resultsFor both Elecsys and Lumipulse the p-tau/Aβ DISCUSSION: Biomarker ratios p-tau/Aβ
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.